Tumor Response

Top banner braf

The majority of patients with measurable disease experienced tumour shrinkage with BRAFTOVI + cetuximab vs control arm*

*Irinotecan based treatment regimen

Best percentage change in tumour response per primary analysis3,a

BRAFTOVI + cetuximab VS FOLFIRI + cetuximab or irinotecan + cetuximab


Reprinted with permission from Massachusetts Medical Society.


  • The sum of longest diameter change includes patients with measurable disease per RECIST v1.1 with a baseline and at least 1 post-baseline scan. Only patients with measurable disease are included in the above waterfall plots3,8

a The asterisks indicate patients who had a complete response, partial response, or stable disease with respect to target lesions but who had a new lesion, a progressing nontarget lesion, or both.

HealthCare Professionals​

This is an international website for BRAFTOVI dedicated to Healthcare professionals ​​

IMPORTANT: the information on this website is based on the European Summary of Product Characteristics. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

I certify that:

I am Healthcare Professional outside the US and I have read the information above​. 


This is an international website for BRAFTOVI dedicated to Healthcare professionals.

I am a patient outside the US​